Instead, a combination regimen of low, i.e. non-cytotoxic concentrations of Gamitrinib plus TRAIL dramatically killed tumor cells normally resistant to TRAIL, and potently inhibited intracranial glioblastoma growth in mice with no detectable toxicity [6]. This evidence concerns the gene TNFSF10 and neoplasm.